Logo image of ADIL

ADIAL PHARMACEUTICALS INC (ADIL) Stock Fundamental Analysis

NASDAQ:ADIL - Nasdaq - US00688A2050 - Common Stock - Currency: USD

0.2595  +0.01 (+3.8%)

Fundamental Rating

2

ADIL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. ADIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADIL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADIL had negative earnings in the past year.
In the past year ADIL has reported a negative cash flow from operations.
In the past 5 years ADIL always reported negative net income.
In the past 5 years ADIL always reported negative operating cash flow.
ADIL Yearly Net Income VS EBIT VS OCF VS FCFADIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -259.33%, ADIL is doing worse than 92.82% of the companies in the same industry.
ADIL has a Return On Equity of -420.83%. This is in the lower half of the industry: ADIL underperforms 77.44% of its industry peers.
Industry RankSector Rank
ROA -259.33%
ROE -420.83%
ROIC N/A
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
ADIL Yearly ROA, ROE, ROICADIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

ADIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADIL Yearly Profit, Operating, Gross MarginsADIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ADIL has more shares outstanding
The number of shares outstanding for ADIL has been increased compared to 5 years ago.
There is no outstanding debt for ADIL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADIL Yearly Shares OutstandingADIL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADIL Yearly Total Debt VS Total AssetsADIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

ADIL has an Altman-Z score of -41.16. This is a bad value and indicates that ADIL is not financially healthy and even has some risk of bankruptcy.
ADIL's Altman-Z score of -41.16 is on the low side compared to the rest of the industry. ADIL is outperformed by 89.23% of its industry peers.
ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -41.16
ROIC/WACCN/A
WACCN/A
ADIL Yearly LT Debt VS Equity VS FCFADIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 1.99 indicates that ADIL should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.99, ADIL is doing worse than 60.51% of the companies in the same industry.
A Quick Ratio of 1.99 indicates that ADIL should not have too much problems paying its short term obligations.
ADIL's Quick ratio of 1.99 is in line compared to the rest of the industry. ADIL outperforms 43.08% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
ADIL Yearly Current Assets VS Current LiabilitesADIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.57% over the past year.
EPS 1Y (TTM)25.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ADIL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.07% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.67%
EPS Next 2Y21.08%
EPS Next 3Y19.5%
EPS Next 5Y16.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADIL Yearly Revenue VS EstimatesADIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
ADIL Yearly EPS VS EstimatesADIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADIL. In the last year negative earnings were reported.
Also next year ADIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADIL Price Earnings VS Forward Price EarningsADIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADIL Per share dataADIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ADIL's earnings are expected to grow with 19.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.08%
EPS Next 3Y19.5%

More info and screens

0

5. Dividend

5.1 Amount

ADIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADIAL PHARMACEUTICALS INC

NASDAQ:ADIL (6/23/2025, 3:07:01 PM)

0.2595

+0.01 (+3.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners7.27%
Inst Owner Change-18.76%
Ins Owners1.09%
Ins Owner Change0%
Market Cap2.05M
Analysts80
Price Target6.63 (2454.91%)
Short Float %1.72%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)9.7%
Max EPS beat(2)32.66%
EPS beat(4)3
Avg EPS beat(4)10.99%
Min EPS beat(4)-8.12%
Max EPS beat(4)32.66%
EPS beat(8)4
Avg EPS beat(8)5.8%
EPS beat(12)7
Avg EPS beat(12)10.33%
EPS beat(16)9
Avg EPS beat(16)6.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.63%
EPS NY rev (1m)-12.21%
EPS NY rev (3m)-47.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -259.33%
ROE -420.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z -41.16
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
EPS Next Y-4.67%
EPS Next 2Y21.08%
EPS Next 3Y19.5%
EPS Next 5Y16.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.38%
OCF growth 3YN/A
OCF growth 5YN/A